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SUMMARY  
  
The  cerebral  cavernous  malformation  (CCM)  pathway  is  required  in  endothelial  
cells  for  normal  cardiovascular  development  and  to  prevent  postnatal  vascular  
malformations,  but  its  molecular  effectors  are  not  well  defined.    Here  we  show  that  loss  
of  CCM  signaling  in  endocardial  cells  results  in  mid-­gestation  heart  failure  associated  
with  premature  degradation  of  cardiac  jelly.  CCM  deficiency  dramatically  alters  
endocardial  and  endothelial  gene  expression,  including  increased  expression  of  the  Klf2  
and  Klf4  transcription  factors  and  the  Adamts4  and  Adamts5  proteases  that  degrade  
cardiac  jelly.    These  changes  in  gene  expression  result  from  increased  activity  of  
MEKK3,  a  mitogen-­activated  protein  kinase  that  binds  CCM2  in  endothelial  cells.  
MEKK3  is  both  necessary  and  sufficient  for  expression  of  these  genes,  and  partial  loss  of  
MEKK3  rescues  cardiac  defects  in  CCM-­deficient  embryos.    These  findings  reveal  a  
molecular  mechanism  by  which  CCM  signaling  controls  endothelial  gene  expression  
during  cardiovascular  development  that  may  also  underlie  CCM  formation.  
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INTRODUCTION  
   Embryonic  heart  growth  requires  the  coordinated  expansion  and  patterning  of  two  
major  cell  types,  endothelial  cells  that  line  the  lumen  of  the  cardiac  chambers  and  
contractile  myocardial  cells  that  pump  blood.    These  cell  types  support  and  interact  with  
each  other  through  secreted  factors,  i.e.  endocardial-­secreted  growth  factors  such  as  
neuregulin  and  FGFs  that  stimulate  myocardial  proliferation  (Gassmann  et  al.,  1995;;  
Lavine  et  al.,  2005)  and  myocardial-­derived  factors  such  as  angiopoietin  (Jeansson  et  al.,  
2011)  that  support  endocardial  growth.    Loss  of  endocardial-­myocardial  signaling  results  
in  a  failure  of  cardiac  growth  and  embryonic  lethality  (Gassmann  et  al.,  1995).    Similar  
phenotypes  arise  in  human  patients  with  cardiac  non-­compaction  (Jenni  et  al.,  1999).    
During  the  early,  most  rapid  period  of  cardiac  growth  (E8.5-­E14.5  in  the  mouse),  
abundant  extracellular  matrix  known  collectively  as  cardiac  jelly  separates  the  
endocardium  and  myocardium  (Nakamura  and  Manasek,  1981).    Cardiac  jelly  consists  of  
glycoaminoglycans  such  as  hyaluronic  acid  (HA),  and  HA-­binding  proteins  such  as  
versican.  Loss  of  either  HA  synthase  or  versican  results  in  a  thin  myocardium  that  fails  to  
proliferate  and  form  normal  trabeculae  (Camenisch  et  al.,  2000;;  Yamamura  et  al.,  1997).    
As  the  heart  matures  and  trabeculation  is  completed,  cardiac  jelly  is  lost  and  myocardial  
proliferation  slows.    Recent  genetic  studies  in  mice  have  implicated  endocardial  
expression  of  secreted  proteases  such  as  ADAMTS1  and  ADAMTS5  that  degrade  
versican  in  the  regulation  of  cardiac  jelly  and  heart  valve  formation  (Dupuis  et  al.,  2011;;  
Stankunas  et  al.,  2008),  but  the  upstream  signaling  pathways  that  control  endothelial  
expression  of  such  proteases  and  thereby  regulate  cardiac  growth  remain  largely  
unknown.  
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The  cerebral  cavernous  malformation  (CCM)  signaling  pathway  was  discovered  
through  genetic  studies  of  human  patients  with  familial  vascular  malformations  (Chan  et  
al.,  2010;;  Riant  et  al.,  2010).    These  studies  have  identified  loss  of  function  mutations  in  
three  genes,  KRIT1,  CCM2  and  PDCD10  (reviewed  in  Riant  et  al.,  2010)  that  encode  
intracellular  adaptor  proteins  that  associate  to  form  a  biochemical  complex  with  the  
transmembrane  protein  Heart  of  Glass  (HEG1)  (Kleaveland  et  al.,  2009;;  Zheng  et  al.,  
2010).  Conditional  deletion  studies  in  mice  have  demonstrated  that  KRIT1  and  CCM2  
are  required  in  endothelial  cells  for  branchial  arch  artery  formation  at  E8.5-­9  (Whitehead  
et  al.,  2009;;  Whitehead  et  al.,  2004;;  Zheng  et  al.,  2010),  and  to  prevent  CCM  formation  
in  the  central  nervous  system  of  postnatal  animals  (Boulday  et  al.,  2011;;  Chan  et  al.,  
2011;;  McDonald  et  al.,  2011).    How  CCM  signaling  regulates  endothelial  and  vascular  
function  remains  unclear.    Cell  culture  studies  and  pharmacologic  studies  in  mice  have  
linked  CCM  signaling  to  negative  regulation  of  RhoA  activity  (Glading  et  al.,  2007;;  
Stockton  et  al.,  2010;;  Whitehead  et  al.,  2009;;  Zheng  et  al.,  2010)  and  TGFb  (Maddaluno  
et  al.,  2013),  but  definitive  evidence  for  a  causal  relationship  to  these  pathways  or  other  
GRZQVWUHDP&&0HIIHFWRUVWKDWFOHDUO\H[SODLQWKHSDWKZD\¶VIXQFWLRQLQYDVFXODU
development  and  maintenance  has  been  lacking.  
A  role  for  CCM  signaling  in  the  developing  heart  was  first  revealed  by  zebrafish  
embryos  lacking  heg1,  krit1,  ccm2,  and  pdcd10  that  exhibited  a  characteristic  dilated  
heart  phenotype  (Mably  et  al.,  2006;;  Mably  et  al.,  2003;;  Zheng  et  al.,  2010).    In  the  
developing  mouse,  Heg  is  strongly  expressed  in  the  endocardium  and  its  loss  results  in  
patchy  areas  of  thin  myocardium  and  cardiac  rupture  in  late  gestation  (Kleaveland  et  al.,  
2009;;  Zheng  et  al.,  2012).    We  have  also  recently  identified  a  CCM2  orthologue,  
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CCM2L,  that  is  expressed  selectively  in  the  endocardium  of  the  developing  heart  where  it  
regulates  cardiac  growth  (Zheng  et  al.,  2012).  A  major  impediment  to  defining  the  role  of  
the  CCM  pathway  in  cardiac  development  in  mice  has  been  early  lethality  due  to  vascular  
defects  that  prevent  blood  circulation.    In  the  present  study  we  use  an  Nfatc1Cre  allele  to  
delete  CCM  pathway  genes  specifically  in  the  endocardium  and  bypass  this  vascular  
requirement  (Wu  et  al.,  2012).    We  find  that  loss  of  endocardial  CCM  signaling  results  in  
embryonic  heart  failure  and  reduced  myocardial  growth  that  is  characterized  by  loss  of  
cardiac  jelly  and  preserved  expression  of  endocardial  growth  factors.    This  phenotype  is  
caused  by  increased  expression  of  the  Klf2  and  Klf4  transcription  factors  and  the  Adamts4  
and  Adamts5  proteases  that  degrade  the  cardiac  jelly  protein  versican.    CCM-­deficient  
endothelial  gene  expression  changes  are  associated  with  increased  activity  of  the  MEKK3  
signaling  pathway,  and  CCM-­deficient  changes  in  cultured  endothelial  cells  and  
embryonic  mouse  and  fish  hearts  are  rescued  by  reduced  MEKK3  expression  or  activity.    
These  studies  define  regulation  of  MEKK3  signaling  and  endothelial  gene  expression  as  a  
conserved  mechanism  by  which  CCM  signaling  functions  in  the  developing  heart,  and  
raise  the  possibility  that  loss  of  this  molecular  regulatory  mechanism  may  also  participate  
in  CCM  formation.
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RESULTS  
Nfatc1Cre  drives  recombination  in  the  endocardium  but  not  in  the  endothelium  of  
developing  BAAs  or  peripheral  vessels  
   Previous  studies  of  global  and  endothelial-­specific  loss  of  Krit1  and  Ccm2  
revealed  embryonic  lethality  at  E8.5-­9.5  due  to  a  lack  of  lumenized  branchial  arch  
arteries  (BAAs)  and  blood  circulation  (Boulday  et  al.,  2009;;  Whitehead  et  al.,  2009;;  
Whitehead  et  al.,  2004;;  Zheng  et  al.,  2010),  a  severe  vascular  phenotype  that  was  also  
observed  in  zebrafish  embryos  lacking  HEG-­CCM  signaling  (Zheng  et  al.,  2010).    
Cardiac  defects,  such  as  atrial  enlargement,  reduced  trabeculation  and  pericardial  edema,  
were  noted  in  deficient  mouse  embryos  (Boulday  et  al.,  2009;;  Whitehead  et  al.,  2004),  
but  since  these  changes  arose  in  animals  with  complete  vascular  disruption  it  was  not  
clear  if  they  were  primary  or  secondary  phenotypes.  
To  circumvent  the  early  requirement  for  CCM  signaling  in  the  BAA  endothelium  
and  investigate  the  role  of  CCM  signaling  specifically  in  the  heart,  we  used  Nfatc1Cre  
mice  (Wu  et  al.,  2012).    Consistent  with  published  studies,  lineage  tracing  studies  in  
Nfatc1Cre;;R26R-­YFP  animals  revealed  Nfatc1Cre  activity  throughout  the  atrial  and  
ventricular  endocardium,  but  not  in  the  endothelium  of  the  distal  aortic  sac  or  the  
developing  BAAs  at  E10.5  (Fig.  S1A-­F).    Nfatc1Cre  activity  was  observed  in  endothelial  
cells  of  the  ascending  aorta  and  proximal  pulmonary  arteries  at  E14.5,  but  not  in  more  
distal  great  vessels  at  that  timepoint  (Fig.  S1G-­K)  or  in  the  endothelial  cells  of  the  
peripheral  vasculature  in  the  liver  or  kidney  at  P1  (Fig.  S1L-­R).  These  studies  suggested  
that  Nfatc1Cre  could  be  used  to  test  the  requirement  for  CCM  signaling  specifically  within  
the  endocardium  of  the  developing  heart.  
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Endocardial  deletion  of  Krit1  results  in  mid-­gestation  heart  failure  associated  with  loss  
of  cardiac  jelly.  
Analysis  of  Nfatc1Cre;;Krit1fl/+  X  Krit1fl/fl  crosses  at  P0.5  revealed  that  
Nfatc1Cre;;Krit1fl/fl  mice  die  prior  to  birth  (Supp.  Table  1).    Timed  matings  demonstrated  
live  Nfatc1Cre;;Krit1fl/fl  embryos  that  were  grossly  indistinguishable  from  littermate  
controls  at  E12.5  (Fig.  S2),  but  all  Nfatc1Cre;;Krit1fl/fl  embryos  were  dead  by  E14.5-­15.5  
(Fig.  S2  and  Table  S1).  Thus  endocardial  loss  of  KRIT1  results  in  embryonic  lethality  
during  mid-­gestation.  
To  understand  the  cause  of  lethality,  Nfatc1Cre;;Krit1fl/fl  and  control  littermates  
were  examined  at  E10.5  and  E12.5,  timepoints  prior  to  lethality.    H-­E  staining  of  
Nfatc1Cre;;Krit1fl/fl  hearts  at  E10.5  revealed  thin  myocardium  and  smaller  myocardial  
trabeculae  compared  with  littermate  controls,  despite  the  presence  of  abundant  
endocardial  cells  (Fig.  1A,  B).    These  changes  were  more  marked  at  E12.5,  when  control  
hearts  had  developed  a  thicker  compact  myocardium  and  well-­developed  trabeculae  (Fig.  
1C,  D).    Atrial  and  ventricular  chamber  dilatation,  like  that  observed  in  ccm-­deficient  
zebrafish  embryos  (e.g.  Fig.  4  and  (Mably  et  al.,  2006;;  Mably  et  al.,  2003)),  were  also  
observed  in  Nfatc1Cre;;Krit1fl/fl  embryos  at  E12.5  (e.g.  Fig.  1C  vs.  1D).    Most  striking  was  
the  reduction  in  space  between  the  endocardium  and  myocardium  that  is  occupied  by  
cardiac  jelly  in  Nfatc1Cre;;Krit1fl/fl  embryo  hearts  at  E10.5  and  E12.5  (Fig.  1A-­D).    This  
phenotype  was  particularly  evident  in  the  trabeculae,  where  the  myocardium  was  
wrapped  tightly  by  endocardium  in  the  Nfatc1Cre;;Krit1fl/fl  heart  but  clearly  separated  from  
the  endocardium  in  control  hearts  at  these  timepoints  (arrows,  Fig.  1A-­D).    Quantitation  
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of  the  area  occupied  by  cardiac  jelly  in  the  trabeculae  of  the  E10.5  heart  revealed  an  
>65%  decrease  in  Nfatc1Cre;;Krit1fl/fl  hearts  compared  with  either  Krit1fl/fl  or  
Nfatc1Cre;;Krit1fl/+  littermate  hearts  (Fig.  1E).  
The  loss  of  endocardial-­myocardial  separation  in  Nfatc1Cre;;Krit1fl/fl  hearts  
suggested  that  endocardial  loss  of  CCM1  results  in  reduced  cardiac  matrix/jelly.    
Consistent  with  this  observation,  Alcian  blue  staining  demonstrated  loss  of  matrix  
glycosaminoglycans  in  the  Nfatc1Cre;;Krit1fl/fl  heart,  particularly  surrounding  the  
trabeculae  at  E10.5  (Fig.  1F,  G).  Versican  is  the  major  protein  component  of  cardiac  
jelly,  and  loss  of  versican  results  in  reduced  myocardial  growth  and  failure  to  form  
myocardial  trabeculae.    Immunostaining  revealed  a  severe  loss  of  intact  versican  in  the  
E10.5  Nfatc1Cre;;Krit1fl/fl  heart  compared  with  controls  (Fig.  1H,  I).    Thus  endocardial  loss  
of  KRIT1  results  in  mid-­gestation  heart  failure  associated  with  reduced  cardiac  jelly.  
  
Endocardial  loss  of  Ccm2  and  Pdcd10  also  result  in  loss  of  cardiac  jelly.  
   In  the  CCM  signaling  pathway  KRIT1  binds  CCM2  and  CCM2  binds  PDCD10  to  
form  a  ternary  complex  (Hilder  et  al.,  2007;;  Zawistowski  et  al.,  2005;;  Zhang  et  al.,  2007),  
and  deficiency  of  any  of  these  three  proteins  results  in  CCM  formation  in  human  patients  
and  in  mouse  models  of  postnatal  endothelial  deficiency  (Boulday  et  al.,  2009;;  Boulday  
et  al.,  2011;;  Whitehead  et  al.,  2009;;  Whitehead  et  al.,  2004).    However,  KRIT1  also  
regulates  integrin  affinity  through  its  interaction  with  ICAP1  (Liu  et  al.,  2013)  and  binds  
RAP1  (Serebriiskii  et  al.,  1997).    Thus  the  role  of  KRIT1  in  the  endocardium  of  the  
developing  heart  might  not  simply  reflect  the  role  for  CCM  signaling  in  that  cell  type.    To  
test  whether  the  cardiac  abnormalities  described  above  arise  due  to  loss  of  canonical  
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CCM  signaling  in  the  endocardium,  we  deleted  Ccm2  and  Pdcd10  in  the  endocardium  
using  Nfatc1Cre.    Nfatc1Cre;;Ccm2fl/fl  embryos  exhibited  embryonic  lethality  at  the  same  
timepoint  as  observed  for  Nfatc1Cre;;Krit1fl/fl  embryos  (Table  S1).  Nfatc1Cre;;Ccm2fl/fl  
embryos  also  exhibited  similar  reductions  in  cardiac  jelly,  myocardial  growth,  Alcian  
blue  staining  and  cardiac  versican  at  both  E10.5  (Fig.  2A-­F)  and  E12.5  (Fig.  2G-­L).    
Nfatc1Cre;;Pdcd10fl/fl  embryos  exhibited  embryonic  lethality  that  was  later  than  that  as  
observed  for  Nfatc1Cre;;Krit1fl/fl  and  Nfatc1Cre;;Ccm2fl/fl  embryos  (Table  S1).    
Nfatc1Cre;;Pdcd10fl/fl  embryos  did  not  appear  abnormal  at  E10.5,  but  reduced  cardiac  jelly,  
myocardial  growth,  Alcian  blue  staining  and  versican  were  observed  at  E12.5  (Fig.  2M-­
R),  consistent  with  a  milder  presentation  of  the  same  phenotype.  These  findings  suggest  
that  all  three  primary  components  of  the  CCM  signaling  pathway  function  in  the  mid-­
gestation  endocardium  to  maintain  cardiac  jelly  and  support  cardiac  growth.  
  
Endocardial  loss  of  KRIT1  is  associated  with  changes  in  the  expression  of  KLF2/4  
transcription  factors  and  ADAMTS4/5  proteases.  
   The  thin  myocardium  and  reduced  cardiac  jelly  observed  in  Nfatc1Cre;;Krit1fl/fl  
hearts  could  result  from  reduced  endocardial  expression  of  myocardial  growth  factors  and  
components  of  the  cardiac  jelly  such  as  hyluronic  acid.  Alternatively,  endocardial  CCM  
signaling  might  be  required  to  prevent  the  expression  of  proteases  such  as  those  in  the  
ADAMTS  family  that  cleave  versican  and  degrade  cardiac  jelly  at  later  timepoints  during  
cardiac  development  (Stankunas  et  al.,  2008;;  Dupuis  et  al.,  2011).    To  address  these  
possible  mechanisms  we  characterized  gene  expression  in  whole  E10.5  Nfatc1Cre;;Krit1fl/fl  
and  littermate  control  hearts  using  microarray  and  qPCR  analysis.    Microarray  and  qPCR  
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analysis  revealed  elevated  levels  of  Adamts4  and  Adamts5,  versican-­degrading  proteases,  
in  addition  to  Klf2  and  Klf4  and  a  number  of  known  KLF2/4  target  genes,  including  
Nos3,  Aqp1,  Jam2,  Thbd,  and  Palmd  (Dekker  et  al.,  2006;;  Parmar  et  al.,  2006)  (Fig.  3A,  
B  &  D).  Reduced  levels  of  Dll4  and  Tmem100,  genes  previously  associated  with  
myocardial  growth  and  trabeculation  (Grego-­Bessa  et  al.,  2007;;  Somekawa  et  al.,  2012),  
were  also  detected  (Fig.  3A,  C).    Expression  of  the  myocardial  growth  factors  FGF9,  
FGF12  and  FGF16  (Lavine  et  al.,  2005)  was  unaltered,  while  that  of  neuregulin  was  
elevated  in  E10.5  Nfatc1Cre;;Krit1fl/fl  hearts  (Fig.  3C),  indicating  that  reduced  myocardial  
growth  did  not  result  from  reduced  endocardial  expression  of  growth  factors.    The  
expression  of  Versican  and  HA  synthase  were  also  unchanged,  despite  the  dramatic  loss  
of  versican  protein  detected  in  Nfatc1Cre;;Krit1fl/fl  hearts  (Fig.  3D).      In  situ  hybridization  
confirmed  the  increase  in  Klf2  mRNA  in  the  E10.5  Nfatc1Cre;;Krit1fl/fl  heart  (Fig.  3E).    
KLF4  protein  was  not  detected  in  the  endocardium  of  the  heart  chamber  in  control  
animals  at  E10.5,  but  was  present  in  the  nuclei  of  almost  all  the  endocardial  cells  in  the  
E10.5  Nfatc1Cre;;Krit1fl/fl  heart  (Fig.  3F).    Increased  levels  of  KLF2  protein  were  also  
detected  by  western  blot  analysis  of  the  E10.5  Nfatc1Cre;;Krit1fl/fl  heart  (Fig.  3G).    
Significantly,  similar  changes  in  Klf  and  Adamts  gene  expression  were  observed  in  the  
E11.5  Nfatc1Cre;;Pdcd10fl/fl  heart  (Fig.  S2),  consistent  with  a  requirement  for  canonical  
CCM  signaling  in  the  regulation  of  these  genes.  
   The  gene  expression  studies  described  above  suggested  that  excess  ADAMTS4/5  
activity  might  be  the  cause  of  reduced  versican  and  cardiac  jelly  in  Nfatc1Cre;;Krit1fl/fl  
hearts.    To  detect  ADAMTS-­mediated  breakdown  of  versican  we  stained  
Nfatc1Cre;;Krit1fl/fl  and  control  E10.5  hearts  with  antibodies  that  specifically  recognize  a  
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versican  epitope  that  is  exposed  following  cleavage  by  ADAMTS  proWHDVHV³'3($$(´
antibody)  (Sandy  et  al.,  2001).    Despite  the  nearly  complete  loss  of  intact  versican  (Fig.  
1H,  I),  increased  levels  of  ADAMTS-­cleaved  versican  were  detected  in  the  E10.5  
Nfatc1Cre;;Krit1fl/fl  heart  by  immunostaining  with  DPEAAE  antibody  (Fig.  3H).    
Biochemical  analysis  of  whole  E10.5  Nfatc1Cre;;Krit1fl/fl  hearts  confirmed  a  marked  
increase  in  the  levels  of  cleaved  versican  and  ADAMTS5  protease  (Fig.  3I).    These  
findings  tie  the  loss  of  cardiac  jelly  associated  with  endocardial  loss  of  CCM  signaling  to  
changes  in  endocardial  gene  expression.        
  
Loss  of  klf2  or  adamts5  rescues  loss  of  CCM  signaling  in  zebrafish  embryos.  
   Endocardial-­specific  loss  of  CCM  signaling  in  the  mouse  results  in  a  thin,  dilated  
heart  that  lacks  cardiac  jelly/matrix  (Figs.  1  &  2).    This  phenotype  resembles  the  dilated  
heart  in  zebrafish  embryos  lacking  this  pathway  (Mably  et  al.,  2006;;  Mably  et  al.,  2003),  
suggestive  of  a  conserved  role  for  CCM  signaling  in  vertebrate  cardiac  development.    To  
determine  if  loss  of  CCM  signaling  results  in  loss  of  cardiac  jelly/matrix  in  developing  
fish  as  well  as  mice  we  analyzed  sections  of  72  hpf  ccm2  mutant  and  control  littermate  
hearts  using  H-­E  and  Alcian  blue  staining.  Control  hearts  exhibited  a  multicellular  layer  
of  myocardium,  with  detectable  Alcian  blue-­stained  cardiac  jelly  between  the  endocardial  
and  myocardial  cell  layers  (Fig.  4A,  B,  C).    In  contrast,  ccm2  mutant  hearts  exhibited  a  
thin,  single-­cell  layer  of  myocardium,  and  no  Alcian  blue  staining  was  detected  in  
sections  that  sampled  the  entire  heart  (Fig.  4D,  E,  F,  N=4  embryos  studied  for  each  
genotype).    Thus  CCM  signaling  deficiency  results  in  the  loss  of  cardiac  jelly  in  both  fish  
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and  mouse  embryos,  consistent  with  a  conserved  role  for  this  pathway  during  heart  
development.  
Molecular  analysis  of  E10.5  Nfatc1Cre;;Krit1fl/fl  and  E10.5  Nfatc1Cre;;Pdcd10fl/fl  
mouse  hearts  revealed  significant  up-­regulation  of  Klf2/4  and  Adamts4/5  gene  expression,  
suggesting  that  these  genes  might  play  causal  roles  in  the  cardiac  phenotype.    To  
functionally  test  a  conserved  role  for  regulation  of  KLF2  and  ADAMTS5  by  CCM  
signaling  we  next  studied  72  hpf  zebrafish  embryos  following  injection  of  morpholinos  to  
block  expression  of  krit1,  with  or  without  co-­injection  of  morpholinos  to  block  klf2a  and  
klf2b  (the  two  zebrafish  Klf2  orthologues)  or  adamts5  (the  sole  zebrafish  Adamts5  
orthologue).    krit1  morpholinos  resulted  in  a  dilated  heart  in  approximately  80%  of  
embryos  at  72  hpf  (Fig.  4G,  J).    When  combined  with  low  dose  klf2a/b  morpholinos  (1.5  
ng  each)  that  resulted  in  a  reduction  of  approximately  50%  in  klf2  dosage  (Fig.  S3),  we  
observed  highly  efficient  rescue  of  the  big  heart  phenotype  (approximately  90%  rescue  
efficiency,  P<0.001)  (Fig.  4H,  J).    Co-­injection  of  morpholinos  targeting  the  exon  2  
splice  acceptor  and  donor  sites  of  adamts5  (5+1  ng,  a  combination  chosen  to  minimize  
morpholino  dose  and  toxicity,  Supp.  Fig.  4C,  D)  also  resulted  in  a  significant  rescue  of  
the  big  heart  phenotype  (approximately  50%  rescue  efficiency,  P<0.001)  (Fig.  4I,  J).  To  
ensure  that  rescue  was  not  merely  due  to  interference  with  krit1  morpholinos,  klf2  or  
adamts5  morpholinos  were  injected  into  embryos  generated  by  ccm2+/-­  intercrosses.    As  
expected,  a  big  heart  phenotype  was  observed  in  approximately  25%  of  control  offspring  
at  72  hpf  (Fig.  4K).    However,  this  cardiac  phenotype  was  observed  in  only  7%  and  16%  
of  offspring  injected  with  klf2a/b  or  adamts5  morpholinos  respectively  (indicative  of  a  
70%  and  35%  rescue  efficiency  for  klf2  and  adamts5  respectively;;  P<0.01  and  P<0.05)  
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(Fig.  4K).    The  lower  efficiency  of  mutant  rescue  compared  with  morphant  rescue  most  
likely  reflects  the  greater  loss  of  CCM  signaling  in  ccm2-­/-­  mutants  compared  with  krit1  
morphants.    These  studies  suggest  that  a  critical  and  conserved  role  of  CCM  signaling  in  
the  developing  heart  is  to  negatively  regulate  the  expression  of  Klf2  and  Adamts5.    
  
MEKK3  regulates  KLF  and  ADAMTS  gene  expression  in  cultured  endothelial  cells  
and  in  embryonic  endocardium.    
The  findings  described  above  revealed  that  CCM  signaling  negatively  regulates  
Klf2  and  Adamts5  gene  expression,  but  studies  of  signaling  by  the  CCM  adaptor  proteins  
have  not  defined  a  transcriptional  mechanism  of  action.    How  are  these  pathways  linked?  
MEKK3  was  identified  as  a  CCM2  binding  partner  a  decade  ago  (Uhlik  et  al.,  2003),  and  
MEKK3  signaling  is  known  to  regulate  gene  expression  through  downstream  effectors  
such  as  ERK5  and  MEF2C  (Chao  et  al.,  1999;;  Nakamura  and  Johnson,  2003),  as  well  as  
p38  and  JNK  (Deacon  and  Blank,  1999;;  Nebreda  and  Porras,  2000).    We  therefore  next  
explored  the  possibility  that  CCM  signaling  might  alter  expression  of  KLF2  and  
ADAMTS5  through  effects  on  the  MEKK3  pathway.    Since  available  anti-­CCM2  
antibodies  are  unable  to  detect  the  protein  in  cultured  endothelial  cells,  to  determine  if  
MEKK3  interacts  with  CCM  proteins  in  endothelial  cells  we  used  tetracycline-­regulable  
lentiviral  vectors  to  express  an  BirA-­MEKK3  fusion  protein  in  hCMEC/D3  endothelial  
cells  (Weksler  et  al.,  2005)  (Fig.  S4).    Using  this  approach  MEKK3-­interacting  proteins  
were  biotinylated  in  live  endothelial  cells  (Roux  et  al.,  2012).    Biotinylated  proteins  were  
captured  by  streptavidin  beads  and  subjected  to  mass  spectrometry  analysis.  When  BirA-­
MEKK3  was  expressed  at  endogenous  levels  (4  ng/ml  doxycycline,  Fig.  S4A),  no  
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specific  MEKK3-­interacting  proteins  were  identified  (not  shown),  perhaps  due  to  kinase  
inactivity.    At  slightly  higher  expression  levels  (8  ng/ml  doxycycline)  peptides  from  only  
4  interacting  proteins  were  identified  (Fig.  S4).    The  most  abundant  of  these  was  CCM2  
(Fig.  S4E).    KRIT1  was  also  detected  at  a  lower  level  equivalent  to  that  of  TRAF7,  an  
MEKK3-­interacting  protein  previously  identified  using  tandem  affinity  purification  
(Bouwmeester  et  al.,  2004).    A  similar  result  was  obtained  when  BirA-­MEKK3  was  
expressed  in  primary  HUVECs  (Fig.  S4F).    These  studies  indicate  that  MEKK3  interacts  
with  the  CCM  protein  complex  in  live  endothelial  cells.  
To  determine  if  MEKK3  regulates  endothelial  gene  expression  in  a  manner  that  
might  explain  the  changes  observed  following  loss  of  CCM  signaling  we  next  tested  
whether  MEKK3  is  sufficient  and/or  required  for  KLF  and  ADAMTS  gene  expression  in  
cultured  endothelial  cells.    Over-­expression  of  MEKK3  using  the  doxycycline  regulable  
system  described  above  resulted  in  dose-­dependent  increases  in  the  levels  of  KLF2  and  
KLF4  expression  in  hCMEC/D3  endothelial  cells  (Fig.  5A).    To  determine  whether  
MEKK3  regulates  KLF  gene  expression  in  response  to  more  physiologic  stimuli  we  
tested  the  role  of  MEKK3  in  endothelial  responses  to  fluid  flow.    Flow  and  fluid  shear  
forces  are  established  regulators  of  KLF2  and  KLF4  expression  in  endothelial  cells  ex  
vivo  (Huddleson  et  al.,  2004;;  Parmar  et  al.,  2006;;  Sohn  et  al.,  2005;;  Villarreal  et  al.,  
2010)  and  in  humans  (Dekker  et  al.,  2006),  mice  (Dekker  et  al.,  2006;;  Lee  et  al.,  2006),  
chick  (Groenendijk  et  al.,  2005)  and  fish  (Vermot  et  al.,  2009)  in  vivo.  Up-­regulation  of  
KLF2  in  response  to  flow  has  been  shown  to  be  mediated  by  MEK5-­ERK5  signaling(Li  
et  al.,  2008;;  Parmar  et  al.,  2006),  one  of  the  pathways  directly  regulated  by  
MEKK3(Chao  et  al.,  1999;;  Nakamura  and  Johnson,  2003).  Consistent  with  prior  studies  
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(Parmar  et  al.,  2006;;  Sohn  et  al.,  2005),  human  umbilical  vein  endothelial  cells  
(HUVECs)  exposed  to  laminar  shear  for  16  hours  exhibited  increased  KLF2,  KLF4  and  
ADAMTS4  expression  (Fig.  5B).      Transfection  with  siRNAs  directed  against  MEKK3  
that  resulted  in  a  40%  knockdown  in  MEKK3  expression  blocked  the  rise  in  expression  of  
KLF2,  KLF4  and  ADAMTS4  induced  by  flow  (Fig.  5B).    These  studies  reveal  that  KLF  
and  ADAMTS  expression  are  regulated  by  MEKK3  in  cultured  endothelial  cells.  
To  determine  whether  MEKK3  also  regulates  these  genes  in  the  E10.5  heart  we  
next  generated  Nfatc1Cre;;Map3k3fl/-­  animals.    Nfatc1Cre;;Map3k3fl/-­  animals  did  not  survive  
to  birth,  and  timed  matings  revealed  embryonic  lethality  prior  to  E12.5  (Table  S1).    
Analysis  of  Nfatc1Cre;;Map3k3fl/-­  embryonic  heart  sections  revealed  a  thin  myocardial  cell  
layer  with  preserved  cardiac  jelly  and  normal  endocardial-­myocardial  separation  at  E10.5  
(Fig.  S5A).    In  contrast  to  endocardial  loss  of  CCM  signaling,  versican  levels  were  
preserved  in  the  E10.5  Nfatc1Cre;;Map3k3fl/-­  heart  (Fig.  S5B).    Gene  expression  analysis  of  
E10.5  Nfatc1Cre;;Map3k3fl/-­  and  control  littermate  hearts  revealed  severe  (>90%)  
reductions  in  the  expression  of  Klf2  and  the  known  KLF2  target  genes  Nos3,  Aqp1,  Jam2,  
Thbd,  and  Palmd,  as  well  as  Klf4,  Adamts4  and  Adamts5  (Fig.  5C,  D).    FGF  gene  
expression  was  unchanged  but  the  expression  of  Nrg1  was  severely  reduced  (Fig.  5D).    
Thus  loss  of  MEKK3  confers  gene  expression  changes  that  are  precisely  reciprocal  to  
those  conferred  by  loss  of  KRIT1  or  PDCD10.    To  determine  whether  MEKK3  regulates  
Klf  and  Adamts  gene  expression  through  the  ERK5  MAPK  pathway  we  cultured  wild-­
type  E10.5  explanted  hearts  in  the  presence  of  BIX02189,  a  highly  specific  inhibitor  of  
MEK5,  the  MAPK2K  that  is  activated  by  MEKK3  and  in  turn  activates  ERK5  (Tatake  et  
al.,  2008).    Treatment  with  BIX02189  resulted  in  reduced  levels  of  Klf2,  Klf4  and  
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Adamts5  expression  (Fig.  5E).    These  findings  demonstrate  that  MEKK3  regulates  KLF  
and  ADAMTS  gene  expression  in  endothelial  cells  ex  vivo  and  in  endocardial  cells  in  vivo  
through  the  MEK5-­ERK5  MAPK  pathway.  
  
Loss  of  MEKK3  rescues  loss  of  CCM  signaling  in  cultured  endothelial  cells  and  
zebrafish  embryo  hearts.  
The  reciprocal  changes  in  gene  expression  observed  with  endocardial  loss  of  
CCM  and  MEKK3  signaling,  the  physical  interaction  between  the  CCM  complex  and  
MEKK3,  and  the  preservation  of  Mekk3  gene  expression  in  Nfatc1Cre;;Krit1fl/fl  hearts  (Fig.  
S6A)  suggested  that  CCM  signaling  might  regulate  endocardial  gene  expression  by  
inhibiting  MEKK3  function.    To  test  the  effect  of  loss  of  CCM  signaling  on  MEKK3  
function  we  used  siRNA  to  knockdown  CCM2  in  HUVECs  and  examined  downstream  
MEKK3  signaling  through  ERK5.    HUVECs  treated  with  CCM2  siRNA,  but  not  with  
scrambled  siRNA,  exhibited  increased  phospho-­ERK5  with  no  change  in  total  ERK5  or  
GAPDH  protein  (Fig.  6A),  consistent  with  an  increase  in  MEKK3  pathway  activity.    As  
observed  with  endocardial  deletion  in  the  E10.5  mouse  heart,  loss  of  CCM2  in  HUVEC  
conferred  increased  expression  of  KLF2,  KLF4  and  ADAMTS4  (Fig.  6B-­D).    These  
increases  were  reversed  by  simultaneous  knockdown  of  MEKK3,  consistent  with  CCM  
regulation  of  gene  expression  through  MEKK3.  
To  test  whether  increased  MEKK3  signaling  is  causal  for  CCM-­deficient  
phentoypes  in  vivo  we  first  used  morpholinos  to  reduce  the  levels  of  mekk3  in  krit1  
morphant  and  ccm2  mutant  zebrafish  embryos.    krit1  morpholinos  resulted  in  a  dilated  
heart  in  approximately  65%  of  embryos  at  72  hpf  in  these  studies  (Fig.  6E,  F,  H).    When  
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combined  with  low  dose  morpholinos  (3  ng)  that  resulted  in  a  reduction  of  approximately  
40%  in  mekk3  dosage  (Fig.  S7)  but  had  no  independent  effect  on  cardiac  development,  
we  observed  efficient  (approx  75%)  rescue  of  the  krit1  morphant  cardiac  phenotype  
(P<0.001)  (Fig.  6G,  H).    To  ensure  that  rescue  was  not  due  to  interference  with  krit1  
morpholinos,  mekk3  morpholinos  were  injected  into  embryos  generated  by  ccm2+/-­  
intercrosses.    A  big  heart  phenotype  was  observed  in  approximately  18%  of  control  
morpholino  injected  offspring  at  72  hpf,  and  injection  of  low  dose  mekk3  morpholinos  
reduced  this  to  approximately  6%,  consistent  with  a  66%  rescue  efficiency  (P<0.001,  Fig.  
6I).    Thus  loss  of  mekk3  rescues  the  dilated  heart  phenotype  conferred  by  loss  of  either  
krit1  or  ccm2  in  zebrafish  embryos,  suggesting  that  gain  of  MEKK3  signaling  may  
underlie  the  role  of  CCM  signaling  during  cardiac  development.  
  
Mekk3  haplo-­insufficiency  rescues  the  loss  of  cardiac  jelly  and  changes  in  gene  
expression  conferred  by  endocardial  Krit1  deletion.  
Rescue  of  the  big  heart  phenotype  conferred  by  loss  of  CCM  signaling  with  loss  
of  mekk3  expression  in  the  zebrafish  requires  careful  dosing  of  mekk3  morpholinos  to  
avoid  an  independent  mekk3-­deficient  cardiac  defect,  and  the  ability  to  measure  rescue  
using  specific  molecular  and  cellular  endpoints  is  limited  in  the  zebrafish  embryo  heart.    
To  address  these  issues  and  rigorously  test  the  causal  role  of  the  MEKK3  pathway  as  a  
downstream  CCM  effector  in  mammals  we  next  tested  the  ability  of  loss  of  one  Mekk3  
allele  to  rescue  the  specific  changes  in  cardiac  jelly  and  cardiac  gene  expression  in  the  
E10.5  Nfatc1Cre;;Krit1fl/fl  mouse  heart.  Despite  the  expected  loss  in  MEKK3  protein  in  
Map3k3+/-­  hearts  (Fig.  S6C),  Map3k3+/-­  animals  and  Nfatc1Cre;;Map3k3fl/+  animals  
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develop  normally,  exhibit  no  changes  in  cardiac  jelly,  and  have  patterns  of  cardiac  gene  
expression  at  E10.5  that  are  indistinguishable  from  Map3k3fl/fl  littermates  ((Yang  et  al.,  
2000)  and  data  not  shown).    Thus  loss  of  a  single  Mekk3  allele  is  well-­tolerated  and  does  
not  affect  cardiac  development.    At  E10.5  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  exhibited  
significantly  more  cardiac  jelly,  alcian  blue  staining  and  intact  versican  than  was  seen  in  
Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  littermates  (Fig.  7A-­I).    Quantitation  of  the  area  occupied  
by  cardiac  jelly  in  the  trabeculae  of  E10.5  littermate  hearts  revealed  a  >65%  decrease  in  
Nfatc1Cre;;Krit1fl/fl  hearts  compared  with  control  littermates,  but  only  a  25%  decrease  in  
Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  (P<0.001,  Fig.  7J).    Consistent  with  the  rescue  of  
cardiac  jelly,  biochemical  analysis  of  ADAMTS-­proteolyzed  versican  using  anti-­
DPEAAE  antibodies  revealed  increased  versican  breakdown  in  the  Nfatc1Cre;;Krit1fl/fl  
heart  that  was  restored  to  normal  levels  in  the  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  heart  (Fig.  
7K).    qPCR  analysis  of  cardiac  gene  expression  revealed  significantly  reduced  levels  of  
Klf2,  Klf4,  KLF2/4  target  genes,  Adamts4  and  Adamts5,  and  Nrg1,  and  increased  levels  of  
Dll4  and  Tmem100,  in  the  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  heart  compared  with  the  
Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  heart  (Fig.  7L-­N).    The  levels  of  Klf2,  Klf4  and  Adamts5  
gene  expression  were  not  restored  to  normal  in  the  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  heart,  
consistent  with  the  significant  but  incomplete  histologic  rescue.    Thus  virtually  all  of  the  
hallmark  histologic,  biochemical,  and  genetic  changes  observed  with  endocardial  loss  of  
KRIT1  are  rescued  by  endocardial  loss  of  MEKK3,  indicating  that  gain  of  MEKK3  
signaling  plays  a  central,  causal  role  in  the  endothelial  phenotype  conferred  by  loss  of  
CCM  signaling  in  the  developing  heart.    
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DISCUSSION  
   Genetic  studies  in  humans,  mice  and  fish  have  revealed  that  CCM  signaling  is  
required  in  endothelial  cells  for  normal  cardiovascular  development  and  to  prevent  
vascular  malformations  after  birth,  but  the  molecular  basis  for  these  phenotypes  has  
remained  elusive.  We  have  used  studies  of  cultured  endothelial  cells,  endocardial-­specific  
deletion  in  the  developing  mouse,  and  genetic  rescue  of  the  CCM-­deficient  heart  
phenotype  in  both  mice  and  zebrafish  to  reveal  a  molecular  mechanism  by  which  the  
CCM  pathway  regulates  endothelial  gene  expression.    Our  studies  demonstrate  that  CCM  
signaling  in  the  endocardium  plays  a  critical  and  conserved  role  in  cardiac  development  
through  regulation  of  the  MEKK3  MAPK  signaling  pathway  and  downstream  ADAMTS  
and  KLF  gene  expression.      
   A  role  for  CCM  signaling  in  cardiac  development  was  revealed  by  the  dilated  
heart  phenotype  observed  in  zebrafish  embryos  lacking  this  pathway  (Mably  et  al.,  2006;;  
Mably  et  al.,  2003;;  Zheng  et  al.,  2010),  but  the  molecular  and  cellular  basis  for  this  
phenotype  has  been  unclear.    The  studies  reported  here  demonstrate  that  CCM  signaling  
controls  degradation  of  cardiac  jelly  by  negatively  regulating  endocardial  expression  of  
ADAMTS4/5  and  KLF2/4.    A  causal  role  for  excess  ADAMTS4/5  is  demonstrated  by  a  
dramatic  increase  in  versican  cleavage  associated  with  loss  of  cardiac  jelly  in  the  
Nfatc1Cre;;Krit1fl/fl  mouse  heart  and  by  rescue  of  the  zebrafish  dilated  heart  with  
morpholinos  that  reduced  adamts5  levels.  Expression  of  both  Adamts  and  Klf  genes  is  
severely  reduced  following  endothelial  loss  of  MEKK3  in  vitro  and  in  vivo,  increased  
MEKK3  drives  expression  of  both  genes  in  cultured  endothelial  cells,  rescue  of  krit1  
morphant  and  ccm2  mutant  zebrafish  hearts  was  highly  efficient  with  loss  of  mekk3,  klf2  
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or  adamts5,  and  both  the  histologic  and  molecular  phenotypes  conferred  by  loss  of  
endocardial  CCM  signaling  are  rescued  by  partial  loss  of  MEKK3.  Thus  a  
straightforward  pathway  is  one  in  which  changes  in  MEKK3  signaling  alter  expression  of  
KLF2/4  that  in  turn  controls  expression  of  ADAMTS4/5  (Fig.  7O).    However,  Adamts5  
has  not  been  identified  as  a  KLF2  target  gene  in  cultured  endothelial  cells  (Dekker  et  al.,  
2002;;  Parmar  et  al.,  2005),  and  we  do  not  detect  Adamts5  expression  in  HUVEC.  Thus  
Adamts4/5  may  be  regulated  by  MEKK3  in  a  KLF-­independent  manner,  or  by  KLF2/4  in  
embryonic  endocardium  but  not  in  cultured  endothelial  cells.    It  is  also  likely  that  
MEKK3-­regulated  and  KLF-­regulated  genes  other  than  Adamts4/5  contribute  to  the  
cardiac  phenotype  associated  with  CCM  deficiency.    Two  such  candidates  identified  by  
our  gene  expression  studies  are  Dll4,  a  Notch  ligand  expressed  by  the  endocardium  that  
supports  trabeculation  and  myocardial  proliferation  (Grego-­Bessa  et  al.,  2007),  and  
Tmem100,  an  ALK1  target  gene  that  is  also  specifically  expressed  in  the  endocardium  
and  required  for  cardiac  growth  (Somekawa  et  al.,  2012).    In  this  regard  it  is  intriguing  
that  KLF4  has  recently  been  shown  to  repress  Dll4  expression  in  endothelial  cells  (Hale  
et  al.,  2014).      
   A  key  finding  to  emerge  from  our  studies  is  the  identification  of  a  molecular  
mechanism  by  which  CCM  signaling  regulates  endothelial  gene  expression.    Previous  
studies  of  the  CCM  pathway  have  not  revealed  a  molecular  path  to  transcriptional  
regulation,  although  changes  in  RhoA  activity  (Glading  et  al.,  2007;;  Stockton  et  al.,  2010;;  
Whitehead  et  al.,  2009;;  Zheng  et  al.,  2010)  and  TGFb  signaling  (Maddaluno  et  al.,  2013)  
have  been  reported.    The  findings  that  CCM2  interacts  with  MEKK3  in  endothelial  cells  
and  that  endocardial  loss  of  CCM  signaling  and  MEKK3  confer  precisely  reciprocal  
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changes  in  gene  expression  suggested  that  the  CCM  pathway  may  control  gene  
expression  by  regulating  MEKK3  signaling  (Fig.  7O).    Rescue  of  CCM-­deficient  
phenotypes  in  cultured  endothelial  cells  and  fish  and  mouse  embryos  demonstrates  a  clear  
causal  role  for  increased  MEKK3  function.    Previous  studies  have  linked  MEKK3  to  
three  downstream  MAPK  pathways  by  which  it  might  regulate  gene  expression:  JNK  
(Deacon  and  Blank,  1999),  p38  (Deacon  and  Blank,  1999;;  Uhlik  et  al.,  2003)  and  ERK5  
(Chao  et  al.,  1999;;  Nakamura  and  Johnson,  2003).    However,  our  endothelial  studies  
demonstrate  MEKK3  regulation  of  KLF2/4  and  ADAMTS4  expression  in  response  to  
fluid  flow,  known  to  be  downstream  of  MEK5  and  ERK5  (Li  et  al.,  2008;;  Parmar  et  al.,  
2006;;  Sohn  et  al.,  2005),  and  ex  vivo  embryonic  heart  culture  studies  using  a  highly  
specific  MEK5  inhibitor  identify  the  MEK5-­ERK5  pathway  as  a  key  mechanism  of  gene  
regulation  by  CCM  signaling  (Fig.  5).    Thus  our  studies  support  a  mechanism  in  which  
CCM  signaling  specifically  regulates  the  MEK5-­ERK5  pathway  downstream  of  MEKK3  
in  endothelial  cells.      
   A  final  question  raised  by  our  studies  is  whether  regulation  of  the  MEKK3  
pathway  by  CCM  signaling  observed  in  the  developing  heart  also  plays  an  important  role  
in  the  formation  of  CCMs  in  humans  and  mice.    Loss  of  CCM  signaling  in  the  postnatal  
endothelium  results  in  large  vascular  malformations  (CCMs)  in  the  central  nervous  of  
humans  and  mice  (Akers  et  al.,  2009;;  Boulday  et  al.,  2011;;  Chan  et  al.,  2011;;  McDonald  
et  al.,  2011).    CCMs  are  an  important  cause  of  stroke  for  which  there  is  presently  no  
medical  treatment  (Li  and  Whitehead,  2010).    Drugs  that  inhibit  RhoA  and  TGFb  
signaling  have  been  reported  to  reduce  lesion  frequency  in  mouse  models  of  CCM  
(Maddaluno  et  al.,  2013;;  McDonald  et  al.,  2012),  but  the  responses  have  been  incomplete  
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and  a  clear  molecular  and/or  cellular  basis  for  CCM  formation  is  still  lacking.    
Significantly,  up-­regulation  of  KLF4  expression  was  recently  identified  as  a  prominent  
molecular  phenotype  of  the  endothelial  cells  that  form  CCMs  (Maddaluno  et  al.,  2013),  a  
finding  that  mirrors  the  increase  in  KLF4  observed  in  the  developing  endocardium  and  in  
cultured  endothelial  cells  lacking  CCM  signaling.    It  is  therefore  possible  that  CCM-­
deficient  endothelial  cells  in  the  central  nervous  system  exhibit  increased  MEKK3  
activity  like  that  we  have  observed  in  CCM-­deficient  endocardial  cells,  and  that  changes  
in  gene  expression  resulting  from  increased  MEKK3  activity  also  underlie  CCM  disease  
pathogenesis.    Future  studies  that  test  rescue  of  CCM  formation  in  mice  using  either  
genetic  or  pharmacologic  loss  of  MEKK3  pathway  activity  should  be  able  to  test  this  
clinically  important  hypothesis.    
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EXPERIMENTAL  PROCEDURES  
Mice  
Nfatc1Cre  (Wu  et  al.,  2012),  Ccm2fl/fl  (Zheng  et  al.,  2012),  Pdcd10fl/fl  (Chan  et  al,  2010)  
and  Krit1fl/fl(Mleynek  et  al.,  2014)  animals  have  been  previously  described.  The  
ROSA26-­YFP  reporter  line  was  obtained  from  Jackson  Laboratories  (#006148).  
Map3k3fl/fl  animals  were  generated  as  shown  in  Fig.  S6.    The  University  of  Pennsylvania  
Institutional  Animal  Care  and  Use  Committee  approved  all  animal  protocols.  
  
Histology  
Embryos  and  tissues  were  fixed  in  10%  formaldehyde  overnight,  dehydrated  in  100%  
ethanol,  and  embedded  in  paraffin.  8  µm  thick  sections  were  used  for  hematoxylin  eosin,  
Alcian  blue  and  immunohistochemistry  staining.    Klf2  in  situ  hybridization  was  
performed  as  previously  reported  (Lee  et  al.,  2006).  The  following  antibodies  were  used  
for  immunostaining:  rat  anti-­Pecam  (1:500,  BD  PharMingen),  rabbit  anti-­Versican  
(1:200,  Millipore),  rabbit  anti-­DPEAAE  (1:200,  Pierce-­Antibodies).  
  
Zebrafish  studies  
Zebrafish  were  maintained  and  with  approval  of  the  Institutional  Animal  Care  and  Use  
Committee  of  the  University  of  Pennsylvania.  ccm2hi296  mutant  zebrafish  were  obtained  
from  the  Zebrafish  International  Resource  Center  (ZIRC).  i-­fabp:GFP  transgenic  embryos  
in  which  the  heart  is  fluorescently  labeled  were  kindly  provided  by  Dr.  Michael  Pack.  
The  cardiac  reporter  zebrafish  were  created  by  transposon-­based  gene  trap  approach  
using  the  192bp  zebrafish  I-­FABP  promoter    (Her  et  al.,  2004).  Morpholino  
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oligonucleotides  were  obtained  from  Gene  Tools  (Philomath,  OR)  and  were  injected  into  
the  yolk  of  one-­cell  stage  embryos  at  the  indicated  dosages  and  combinations.      The  
morpholino  sequences  are  described  in  Supplemental  Experimental  Procedures.  
  
Biochemical  studies.    
Biochemical  studies  of  E10.5  Nfatc1Cre;;Krit1fl/fl  hearts  were  performed  as  previously  
described  (Kleaveland  et  al.,  2009;;  Zheng  et  al.,  2010).    The  following  antibodies  were  
used  for  immunonlotting:  rabbit  anti-­Gapdh  (1:5000,  Cell  Signaling),  rabbit anti-pERK5 
(1:1000, Cell Signaling), rabbit  anti-­Adamts5  (1:1000,  Abcam),  rabbit  anti-­DPEAAE  
(1:1000,  Pierce-­Antibodies).    Identification  of  BirA-­MEKK3  interacting  proteins  is  
described  in  Supplemental  Materials  and  Methods. 
  
Endothelial cell studies 
Human umbilical vein endothelial cells (HUVEC; Lonza) were grown in EBM media 
supplemented with EGM-2 SingleQuots (Lonza). HUVECs were transfected overnight 
with 10nM Ambion Silencer Select siRNA against Map3k3 (s8671, Invitrogen) or Ccm2 
(s8671, Invitrogen) using siPORT Amine Transfection Agent (Invitrogen) according to 
WKHPDQXIDFWXUHU¶VSURWRFROKRXUVDIWHUWUDQVIHFWLRQ total RNA was isolated using 
TRIzol Reagent (InvitrogenF'1$ZDVJHQHUDWHGIURPȝJWRWDO51$XVLQJ
Superscript III Reverse Transcriptase (Invitrogen). qPCR was performed in Power SYBR 
Green PCR Master Mix (Applied Biosciences) using primers  described  in  Supplemental  
Materials  and  Methods. 
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Mouse heart explant studies 
Hearts from wild type embryos on mixed background were collected at E10.5 and 
cultured in the presence of BIX02189 (5 uM) or DMSO for 24 h on transwell filters as 
described previously (Lavine  et  al.,  2005).  
  
Statistics  
P  values  were  calculated  using  an  unpaired  2-­WDLOHG6WXGHQW¶VW-­test,  ANOVA,  or  Chi  
Square  analysis  as  indicated.    The  mean  and  standard  error  of  mean  (SEM)  are  shown  in  
the  bar  graphs.  
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Figure  Legends  
  
Figure  1.    Lack  of  endocardial  Krit1  results  in  loss  of  cardiac  jelly.  A-­D.  
Nfatc1Cre;;Krit1fl/fl  hearts  exhibit  thinned  myocardium  and  reduced  space  between  
endocardial  and  myocardial  cells  at  E10.5  and  E12.5.    Arrows  indicate  the  endocardial-­
P\RFDUGLDOJDS$¶-­'¶VKRZKLJKHUPDJQLILFDWLRQLPDJHVRIWKHUHJLRQVER[HGLQ$-­D.  
E.    Ratio  of  the  area  occupied  by  cardiac  jelly  to  that  occupied  by  myocardium  in  the  
trabeculae  of  E10.5  littermate  hearts.    N=3  embryos;;  9  sections  analyzed  for  each  group.    
**  indicates  P<0.01.      F,  G.    Reduced  Alcian  blue  staining  in  Nfatc1Cre;;Krit1fl/fl  hearts  at  
()¶DQG*¶VKRZKLJKHUPDJQLILFDWLRQLPDJHVRIWKHUHJLRQVER[HGLn  F  and  G.    H,  




Figure  2.    Endocardial  loss  of  Ccm2  or  Pdcd10  also  results  in  reduced  cardiac  jelly.  
A,  B.  Thin  myocardium  and  reduced  endocardial-­myocardial  space  in  Nfatc1Cre;;Ccm2fl/fl  
KHDUWVDW($¶DQG%¶VKRZKLJKHUPDJQLILFDWLRQLPDJHVRIWKHUHJLRQVER[HGLQ$
and  B.  C,  D.    Reduced  Alcian  blue  staining  in  Nfatc1Cre;;Ccm2fl/fl  hearts  at  E10.5.    E,  F.      
Reduced  intact  versican  in  in  Nfatc1Cre;;Ccm2fl/fl  hearts  at  E10.5.  G,  H.  Thin  myocardium  
and  reduced  endocardial-­myocardial  space  in  Nfatc1Cre;;Ccm2fl/fl  KHDUWVDW(*¶DQG
+¶VKRZKLJKHUPDJQLILFDWLRQLPDJHVof  the  regions  boxed  in  G  and  H.  I,  J.    Reduced  
Alcian  blue  staining  in  Nfatc1Cre;;Ccm2fl/fl  hearts  at  E12.5.    K,  L.      Reduced  intact  versican  
in  in  Nfatc1Cre;;Ccm2fl/fl  hearts  at  E12.5.  M,  N.  Thin  myocardium  and  reduced  
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endocardial-­myocardial  space  in  Nfatc1Cre;;Pdcd10fl/fl  KHDUWVDW(0¶DQG1¶VKRZ
higher  magnification  images  of  the  regions  boxed  in  M  and  N.    O,  P.    Reduced  Alcian  
blue  staining  in  Nfatc1Cre;;  Pdcd10fl/fl  hearts  at  E12.5.    Q,  R.      Reduced  intact  versican  in  
in  Nfatc1Cre;;  Pdcd10fl/fl  hearts  at  E12.5.  Scale  bars  indicate  100  Pm.  
  
Figure  3.    Loss  of  CCM  signaling  results  in  increased  Klf2  and  Adamts5  expression  
and  function.    A.    Microarray  analysis  of  mRNA  expression  in  E10.5  Nfatc1Cre;;Krit1fl/fl    
and  Krit1fl/+  littermate  hearts  reveals  increased  levels  of  Klf2,  Klf4,  KLF2  target  genes  
and  Adamts5,  and  reduced  levels  of  Dll4  and  Tmem100.      N=  4  for  both  genotypes.    B.  
qPCR  of  E10.5  hearts  reveals  preserved  or  increased  expression  of  Nrg1  and  FGF  growth  
factors  following  endocardial  Krit1  loss.    C.  qPCR  of  E10.5  hearts  reveals  elevated  levels  
of  Klf2  and  established  KLF2  target  genes  following  endocardial  Krit1  loss.    D.  qPCR  
analysis  of  genes  associated  with  cardiac  jelly  matrix  proteins  and  matrix-­degrading  
proteases  in  E10.5  hearts  reveals  elevated  levels  of  Adamts5  following  endocardial  Krit1  
loss.    N=  3  for  Krit1fl/fl,  N=  4  for  Nfatc1Cre;;Krit1fl/+,  N=5  for  Nfatc1Cre;;Krit1fl/fl  in  B-­D.    E.  
In  situ  hybridization  for  Klf2  in  E10.5  Nfatc1Cre;;Krit1fl/fl    and  Krit1fl/fl  littermate  hearts.    F.    
Immunostaining  for  KLF4  protein  (arrows)  and  myocardium  (MF20)  in  E10.5  
Nfatc1Cre;;Krit1fl/fl    and  Krit1fl/fl  littermate  hearts.    G.  Immunoblot  analysis  of  KLF2  
protein  in  whole  E10.5  Nfatc1Cre;;Krit1fl/fl    and  Nfatc1Cre;;Krit1fl/+  and  Krit1fl/fl  littermate  
hearts..  GAPDH  is  shown  as  a  loading  control.    H.    Immunostaining  using  anti-­DPEAAE  
antibody  to  detect  ADAMTS-­cleaved  versican  reveals  increased  levels  in  the  E10.5  
Nfatc1Cre;;Krit1fl/fl  heart.  Boxed  regions  are  shown  at  higher  magnification  on  the  right.    I.  
Immunoblot  analysis  of  lysate  derived  from  whole  E10.5  hearts  reveals  increased  levels  
   36  
of  cleaved  versican  (DPEAAE)  and  the  ADAMTS5  protease  with  endocardial  loss  of  
Krit1.  GAPDH  is  shown  as  a  loading  control.    Scale  bars  indicate  100  Pm.    *  indicates  P  
<0.05;;  **  indicates  P<0.01;;  ***  indicates  P<0.001.  
  
Figure  4.    Loss  of  klf2  or  adamts5  rescues  the  cardiac  phenotype  conferred  by  loss  of  
CCM  signaling  in  zebrafish  embryos.    A-­C.    H-­E  and  Alcian  blue  staining  of  adjacent  
sections  from  a  72  hpf  control  zebrafish  heart  reveal  a  myocardial  wall  with  multiple  cell  
layers  (A)  and  the  presence  of  Alcian  blue-­staining  cardiac  jelly  (B,  C).    D-­F.    H-­E  and  
Alcian  blue  staining  of  adjacent  sections  from  a  72  hpf  ccm2  mutant  heart  reveals  a  thin  
myocardial  wall  (D)  and  lack  of  cardiac  jelly  (E,  F).    C  and  F  are  higher  magnification  
images  of  the  boxed  regions  in  B  and  E  respectively.    G.    Injection  of  zebrafish  embryos  
with  krit1  morpholinos  results  in  a  big  heart  at  72  hpf  detected  by  light  microscopy  and  in  
i-­fabp:GFP  transgenic  embryos  in  which  the  heart  is  fluorescently  labeled.    H.    Injection  
of  morpholinos  targeting  both  krit1  and  the  two  klf2  zebrafish  orthologues  rescues  the  big  
heart  phenotype  at  72  hpf.    I.  Injection  of  morpholinos  targeting  both  krit1  and  adamts5  
rescues  the  big  heart  phenotype  at  72  hpf.    J.    Efficiency  of  rescue  of  the  krit1  morphant  
heart  phenotype  with  klf2  and  adamts5  morpholinos.  ***  indicates  P<0.001.    K.    
Knockdown  of  klf2  or  adamts5  also  rescues  the  cardiac  phenotype  in  ccm2  mutant  
zebrafish  embryos.    The  frequency  of  a  big  heart  phenotype  in  the  offspring  of  ccm2+/-­  
intercrosses  treated  with  control,  klf2  or  adamts5  morpholinos  is  shown.  **  indicates  
P<0.01;;  *  indicates  P<0.05.    The  number  of  total  embryos  analyzed  and  number  
experimental  repeats  (in  parenthesis)  in  J  and  K  are  indicated  above  each  bar.  Scale  bars  
indicate  100  Pm.  
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Figure  5.  MEKK3  regulates  expression  of  KLF  and  ADAMTS  genes  in  cultured  
endothelial  cells  and  in  the  endocardium  of  the  developing  heart.      A.  Tetracycline-­
regulated  expression  of  BirA-­MEKK3  drives  dose-­dependent  expression  of  KLF2  and  
KLF4  in  HUVEC.  B.    siRNA  knockdown  of  MEKK3  in  HUVEC  blocks  flow-­induced  
expression  of  KLF2,  KLF4  and  ADAMTS4.    HUVEC  were  exposed  to  16  hours  of  
laminar  shear  after  exposure  to  siRNA  directed  against  MEKK3  (MAP3K3)  or  control,  
scrambled  siRNA.      N=5;;  P<0.0001.    C.    qPCR  of  E10.5  hearts  reveals  severely  reduced  
levels  of  Klf2,  Klf4  and  known  KLF2/4  target  genes  following  endocardial  Mekk3  
(Map3k3)  deletion.  N=  3  for  all  groups.      D.    qPCR  of  E10.5  hearts  reveals  reduced  levels  
of  Nrg1  and  Adamts5  but  normal  levels  of  FGFs  following  endocardial  Mekk3  (Map3k3)  
deletion.  N=  3  for  all  groups.    E.    qPCR  of  E9.5  wild-­type  mouse  hearts  following  24  
hour  incubation  in  medium  containing  WKH0(.LQKLELWRU%,;³%,;´RU'062
³FRQWURO´1 IRUDOOJURXSV*  indicates  P  <0.05;;  **  indicates  P<0.01;;  ***  indicates  
P<0.001;;  ****  indicates  P<0.0001.      
  
Figure  6.    Loss  of  MEKK3  rescues  the  CCM-­deficient  phenotype  in  cultured  
endothelial  cells  and  zebrafish  embryos.  
A.    siRNA  knockdown  of  CCM2  increases  the  level  of  phospho-­ERK5  in  cultured  
HUVEC.    B-­D.    siRNA  knockdown  of  CCM2  increases  the  expression  of  KLF2,  KLF4  
and  ADAMTS4  in  HUVEC,  and  these  changes  in  gene  expression  are  reversed  by  siRNA  
knockdown  of  MEKK3  (MAP3K3).    E,  F.    Injection  of  zebrafish  embryos  with  krit1  
morpholinos  results  in  a  big  heart  at  72  hpf  in  i-­fabp:GFP  transgenic  embryos  in  which  
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the  heart  is  fluorescently  labeled.    G.    Injection  of  morpholinos  targeting  both  krit1  and  
map3k3  rescues  the  big  heart  phenotype  at  72  hpf.    H.    Efficiency  of  rescue  of  the  krit1  
morphant  heart  phenotype  with  map3k3  morpholinos.  ***  indicates  P<0.001.    I.    
Knockdown  of  map3k3  rescues  the  cardiac  phenotype  in  ccm2  mutant  zebrafish  embryos.    
The  frequency  of  a  big  heart  phenotype  in  the  offspring  of  ccm2+/-­  intercrosses  treated  
with  control  or  map3k3  morpholinos  is  shown.  ***  indicates  P<0.001.    The  number  of  
total  embryos  analyzed  and  number  experimental  repeats  (in  parenthesis)  are  indicated  
above  each  bar  in  H  and  I  .  Scale  bars  indicate  100  Pm.  
  
Figure  7.    Reduced  Mekk3  expression  rescues  the  loss  of  cardiac  jelly  and  changes  in  
gene  expression  conferred  by  endocardial  loss  of  Krit1.  
A-­C.  The  endocardial-­myocardial  space  occupied  by  cardiac  jelly  is  increased  in  
Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  compared  with  Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  
littermates  at  E10.5.    Higher  magnification  images  of  the  boxed  regions  are  shown  on  the  
right.  D-­F.    Alcian  blue  staining  for  cardiac  jelly  is  increased  in  
Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  compared  with  Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  
littermates  at  E10.5.      G-­I.      Versican  in  cardiac  jelly  is  increased  in  
Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  compared  with  Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  
littermates  at  E10.5.    J.    The  ratio  of  the  area  occupied  by  cardiac  jelly  to  that  occupied  
by  myocardium  in  the  trabeculae  is  increased  in  E10.5  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  
hearts  compared  with  Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+    littermates.    N=3  embryos;;  9  sections  
analyzed  for  each  group.      K.  Immunoblot  analysis  of  lysate  derived  from  whole  E10.5  
hearts  reveals  higher  levels  of  cleaved  versican  (DPEAAE)  in  
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Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  hearts  compared  with  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  
littermates.  GAPDH  is  shown  as  a  loading  control.    L-­N.      qPCR  of  E10.5  hearts  reveals  
normalized  expression  of  Klf2,  Klf4,  KLF2/4  target  genes,  Nrg1,  Dll4,  Tmem100,  
Adamts4    and  Adamts5  in  Nfatc1Cre;;Krit1fl/fl;;Map3k3fl/+  hearts  compared  with  
Nfatc1Cre;;Krit1fl/fl;;Map3k3+/+  littermates  at  E10.5.    *  indicates  P  <0.05;;  **  indicates  
P<0.01;;  ***  indicates  P<0.001.    Scale  bars  indicate  100  Pm.  O.  CCM  regulation  of  
MEKK3  activity  and  gene  expression.    The  CCM  complex  binds  MEKK3  through  
interaction  with  CCM2  and  blocks  MEKK3  signaling  (left).    Loss  of  the  CCM  complex  
increases  MEKK3-­ERK5  signaling  and  the  expression  of  Klf2  and  Adamts5,  resulting  in  















Figure S1.  Nfatc1Cre drives endothelial recombination in the heart but not in branchial 
arch arteries or peripheral vessels (related to Figure 1).  A, B.  Analysis of Nfatc1Cre;R26R-
YFP animals at E10.5 reveals uniform expression of YFP in the endocardium.  C-F. Nfatc1Cre 
6XSSOHPHQWDO7H[W	)LJXUHV
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is not active in the endothelial cells that line the branchial arch arteries at E10.5.  G-K. Analysis 
of Nfatc1Cre;R26R-YFP animals at E14.5 reveals endothelial YFP expression in the proximal 
aorta and pulmonary artery but not in the descending aorta.  L-R. Analysis of Nfatc1Cre;R26R-
YFP animals at P1 reveals YFP expression in endothelial cells of the cardiac chambers (L, M) 
and coronary arteries (N), but not the vasculature of the kidney (O, P) or liver (Q, R).  BAA, 
branchial arch artery; AA, ascending aorta; PA, pulmonary artery; DA, descending aorta; CA, 






Figure S2.  Survival of Nfatc1Cre;Krit1fl/fl embryos and gene expression in 
Nfatc1Cre;Pdcd10fl/fl embryos (related to Figures 1 and 2).  A.  Nfatc1Cre;Krit1fl/fl embryos at 
E12.5 and 15.5. Nfatc1Cre;Krit1fl/fl embryos were viable and visually indistinguishable from 
littermate controls at E12.5, but dead by E15.5.  B. qPCR analysis of mRNA expression 
reveals increased levels of Klf2, Klf4,  and KLF2/4 target genes in E10.5 Nfatc1Cre;Pdcd10fl/fl  
compared with Nfatc1Cre;Pdcd10fl/+  and Pdcd10fl/+ littermate hearts like those seen with 
endocardial deletion of Krit1, but of lower magnitude.  C.  qPCR analysis of mRNA expression 
reveals increased levels of Adamts4 and Adamts5 with preserved levels of versican in E10.5 
Nfatc1Cre;Pdcd10fl/fl  hearts as seen following endocardial deletion of Krit1.  N= 4 for all 





Figure S3.  Characterization of klf2 and adamts5 morpholinos (related to Figure 4). A. 
Schematic diagram of morpholinos targeting the splice sites of the klf2a and klf2b genes in 
zebrafish. B. Characterization of knockdown efficiency of klf2 morpholinos by RT-PCR of 30 
hpf zebrafish embryos.   In all cases the lower band, indicated by green arrows, is the 
amplified product of the wild-type mRNA while the upper bands, indicated by red arrows, are 
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those of mRNAs in which intron splicing has been blocked.  The ef1a gene was amplified as a 
control.  C. Schematic diagram of morpholinos targeting the splicing acceptor and donor sites 
of adamts5 genes in zebrafish. D. Characterization of knockdown efficiency of adamts5  
morpholinos by RT-PCR of 30 hpf zebrafish embryos.   The band indicated by green arrow is 
the amplified product of the wild-type mRNA while the upper band indicated by a red arrow is 
that of mRNAs in which intron splicing has been blocked, and the lower band indicated by a 
red arrow is the amplification of mRNA in which exon 2 splicing is skipped.  The ef1a gene was 





Figure S4.  MEKK3 interacts with CCM2 in endothelial cells (related to Figure 5).  A.  
Immunodetection of tetracycline-induced expression of MEKK3-BirA and endogenous MEKK3 
in hCMEC/D3 cells using anti-MEKK3 antibodies.  B.  MS/MS spectrum of an identified CCM2 
peptide, TQDPGISPSQSLCAESSR.  This peptide was doubly charged, and two fragment b 
and y ions (labeled by red and blue) were observed in the generated spectrum.  C.  Mass 
spectrometry identification result of CCM2. Six unique tryptic CCM2 peptides (total eight 
peptide-spectrum matches) were identified. “Start-End” refers to the position of the peptide in 
CCM2; “Observed” indicates the m/z (mass/charge) value detected by mass spectrometry; 
“Mr(expt)” indicates the  detected molecular weight of the peptide; “Mr(calc)” indicates the 
theoretical molecular weight of the peptide; “ppm” represents the mass shift between 
“Mr(expt)” and “Mr(calc)”; “Ion score” is the Mascot score used to identify the peptide.  
D.  Distribution of identified peptides in the CCM2 protein.  Matched peptides are shown in red.  
The sequence coverage for CCM2 was 16%.  E, F. Shown are the number of peptides of the 
indicated proteins detected by MS/MS analysis following streptavidin pulldown of hCMEC/D3 
(E) or human umbilical vein (F) endothelial cells treated with 8 ng/ml doxycycline to induce 
expression of either BirA or BirA-MEKK3. 
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Figure S5.  Endocardial loss of MEKK3 impairs cardiac development but does not alter 
cardiac jelly (related to Figure 5).  A. Nfatc1Cre;Map3k3fl/- hearts exhibit thinned myocardium 
and normal space between endocardial and myocardial cells at E10.5. Boxed regions are 
shown at higher magnification on the right.  Arrows indicate the endocardial-myocardial gap.  




Figure S6.  Mekk3 levels in Nfatc1Cre;Krit1fl/fl and Nfatc1Cre;Map3k3fl/fl embryos (related to 
Figure 6).  A.  Hearts from Nfatc1Cre;Krit1fl/fl  and control embryos were harvested at E10.5 and 
qPCR performed to measure Mekk3 (Map3k3) mRNA levels. N=3; P>0.05.  B. Generation of 
the Map3k3fl allele. A targeting vector was constructed by recombinase mediated cloning to 
introduce loxP sites in introns 8 and 15.  These were used to target Art B6.3.5 (C57BL/6 NTac) 
ES cells (top). Positive colonies were identified by Southern blotting and the presence of the 
point mutation confirmed by Southern bolts of genomic DNA digested with Bam HI using 5’ and 
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3’ probes external to the targeting vector (bottom).  C. MEKK3 protein levels are reduced in 
Map3k3+/- hearts.  MEKK3 protein was detected using western blotting in E10.5 embryo hearts 
from littermates with the indicated genotypes. Map3k3+/- animals were generated by crossing 





Figure S7.  Characterization of map3k3 morpholinos (related to Figure 7). A. Schematic 
diagram of the zebrafish map3k3 allele and the exon 12 donor site targeted by map3k3 
morpholinos. B. Characterization of knockdown efficiency of map3k3 morpholinos by RT-PCR 
of 30 hpf zebrafish embryos.   The upper band, indicated by a green arrow, is the amplified 
product of the wild-type mRNA while the lower band, indicated by a red arrow, is that of 
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mRNAs in which intron splicing has been blocked.  The ef1a gene was amplified as a control.  
C.  Analysis of Fli1-GFP transgenic zebrafish reveals no disruption in vascular development in 




 Table S1.   
 
Live offspring of intercrosses between Nfatc1Cre;Krit1/Ccm2/Pdcd10/Map3k3fl/+ animals 
and Krit1/Ccm2/Pdcd10/Map3k3fl/fl animals were genotyped at the indicated timepoints 
(related to Figures 1, 2 and 5). 
 
  E10.5 E12.5 E14.5 P0 
Total 60 18 24 37 
Krit1fl/+ 21 5 9 14 
Krit1fl/fl 10 6 7 13 
Nfatc1-Cre;Krit1fl/+ 13 3 8 10 
Nfatc1-Cre;Krit1fl/fl 16 4 0* 0** 
     
  E10.5 E12.5 P0 
Total 16 9 27 
Ccm2fl/+ 4 1 6 
Ccm2fl/fl 5 2 13 
Nfatc1-Cre;Ccm2fl/+ 3 3 8 
Nfatc1-Cre;Ccm2fl/fl 4 3 0* 
  E10.5-12.5 E14.5 E15.5-17.5 P0 
Total 66 29 12 24 
Pdcd10fl/+ 13 11 3 9 
Pdcd10fl/fl 19 9 6 9 
Nfatc1-Cre; Pdcd10fl/+ 17 4 3 6 
Nfatc1-Cre; Pdcd1fl/fl 19 5 0 0* 
  E10.5 E11.5 E14.5 P1 
Total 100 55 51 54 
Map3k3fl/+ 29 15 16 14 
Map3k3fl/- 29 23 11 19 
Nfatc1-Cre;Map3k3fl/+ 23 12 24 21 
Nfatc1-Cre;Map3k3fl/- 19 5 0 0 
 




Supplemental Experimental Procedures 
 
Gene expression analysis 
Total RNA was isolated with RNeasy micro kit (Qiagen). Affymatrix mouse gene 2.0st chips 
were used for microarray analysis.  For qPCR analysis, cDNA was synthesized from 1 !g total 
RNA using the Superscript III Reverse Transcriptase (Invitrogen). Real-time PCR was 
performed in Power SYBR Green PCR Master Mix (Applied Biosciences) using the primers 
listed below: 
 
mKlf2 Forward - 5’- CGCCTCGGGTTCATTTC -3’ 
mKlf2 Reverse - 5’- AGCCTATCTTGCCGTCCTTT -3’ 
mKlf4 Forward - 5’- GTGCCCCGACTAACCGTTG-3’ 
mKlf4 Reverse - 5’- GTCGTTGAACTCCTCGGTCT-3’ 
mAqp1 Forward - 5’- CATCACCTCCTCCCTAGTCG -3’ 
mAqp1 Reverse - 5’- CAGTACCAGCTGCAGAGTGC -3’ 
mJam2 Forward - 5’- GATCGTCGCCCTGGACTATC -3’ 
mJam2 Reverse - 5’- GTGACTTCTTGACGGTGGTCT -3’ 
mThbd Forward - 5’- CTCTCCGCACTAGCCAAGC -3’ 
mThbd Reverse - 5’- GGAGCGCACTGTCATCAAATG -3’ 
mPalmd Forward - 5’- ATCTCACAGAAGCGTCTGAAAAT -3’ 
mPalmd Reverse - 5’- CTGCCGATTCCATCCAGGAG -3’ 
mNrg1 Forward - 5’- GAAGAAGCCAGGGAAGTCAGAGCT -3’  
mNrg1 Reverse - 5’- TGGCTGGTCCCAGTCGTGGATGT -3’  
mFgf9 Forward - 5’- GCTCATTGTGGAGACCGATACTT -3’  
mFgf9 Reverse - 5’- TGGCAATTAGCTTCCCCTTCT -3’  
mFgf12 Forward - 5’- ACAGCGACTACACCCTCTTCA -3’  
mFgf12 Reverse - 5’- CTGTTCCCCTTCATGATTTGA -3’  
mFgf16 Forward - 5’- GCTTCCACCTTGAGATCTTCC -3’  
mFgf16 Reverse - 5’- ACTGTTCCCGGAAAACACATT -3’  
mJag1 Forward - 5’- TGGCCGAGGTCCTACACTT -3’  
mJag1 Reverse - 5’- GCCTTTTCAATTATGCTATCAGG -3’  
mDll4 Forward - 5’- AGGTGCCACTTCGGTTACAC -3’  
mDll4 Reverse - 5’- GGGAGAGCAAATGGCTGATA -3’  
mTmem100 Forward - 5’- GACAATGGAGAAAAACCCCAAGA -3’  
mTmem100 Reverse - 5’- GGTAGCAGGAGAGTTCGGC -3’  
mVersican Forward - 5’- ACTAACCCATGCACTACATCAAG -3’  
mVersican Reverse - 5’- ACTTTTCCAGACAGAGAGCCTT -3’  
mHas2 Forward - 5’- TGGGGTGGAAAGAGAGAAGT -3’  
mHas2 Reverse - 5’- ACAGATGAGGCAGGGTCAAG -3’  
mAdamts1 Forward - 5’- CTCTCACCCTTCGGAATTTCTG -3’  
mAdamts1 Reverse - 5’- GGAGCCACATAAATCCTGTCTG -3’  
mAdamts4 Forward - 5’- CAGTGCCCGATTCATCACT -3’  
mAdamts4 Reverse - 5’- GAGTCAGGACCGAAGGTCAG -3’  
mAdamts5 Forward - 5’- CGACCCTCAAGAACTTTTGC -3’  
mAdamts5 Reverse - 5’- CGTCATGAGAAAGGCCAAGT -3’  
mAdamts9 Forward - 5’- TTGGGACCTGCTCAAGAACG -3’  
mAdamts9 Reverse - 5’- ACCATTGATGTTGAAGTGTTTGC -3’  
 
Biotinylation of BirA-MEKK3 interacting proteins in live endothelial cells. 
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MEKK3 was PCR-amplified from pCMV5-MEKK3 (Addgene plasmid 12186). HA-BirA was 
PCR-amplified from mycBioID (Addgene plasmid 35700). The two fragments were ligated to 
create HA-BirA-Mekk3 and cloned into the NotI and MluI sites in the pLVX-TRE3G vector 
(Invitrogen). For a control, BirA-HA was PCR-amplified from MCS-BirA(R118G)-HA (Addgene 
plasmid 36047), and cloned into the ApaI and NotI sites in the pLVX-TRE3G vector.  
hCMEC/D3, an immortalized human brain microvessel endothelial cell line, was grown as 
previously described (Weksler et al., 2005), cotransduced with both the LVX-TRE3G and LVX-
Tet3G lentiviruses, and  selected by G418 and puromycin. Stably transduced hCMEC/D3 cells 
were cultured in doxycycline-containing medium (8 ng/ml) for 3 days to express BirA-Mekk3, 
biotinylation induced as previously described (Roux et al., 2012), and biotinylated proteins 
immunoprecipitated.   
 
Identification of BirA-MEKK3 interacting proteins using NanoLC-MS/MS analysis 
The beads were resuspended in 30ul urea solution (8M urea, 75mM NaCl and 50mM Tris-HCl, 
pH8.3). DTT (10mM) and iodoacetamide (40mM) were added sequentially to reduce and 
alkylate cysteine on proteins. The solution was diluted to 1.5M urea using 50mM Tris-HCl 
(pH8.3). Trypsin (Promage) was added at a ratio of 1:50 (w/w) and proteins were digested 
overnight at room temperature. The beads were kept rotated on a rotator during all above 
steps. After digestion, peptides were desalted using Sep-Pak C18 cartridges (Waters) and the 
eluates were lyophilized.  
NanoLC-MS/MS analysis: NanoLC-MS/MS was performed on a Q Exactive (Thermo Scientific) 
mass spectrometer equipped with EASY-nLC 1000 HPLC. Lyophilized samples were dissolved 
in Buffer A (0.1% formic acid in water) and loaded to a homemade C18 analytical column (75 
µm I.D. " 200 mm) packed with ReproSil-Pur C18-AQ 3 µm resin (Dr. Maisch GmbH). A 
120min LC gradient from 5 to 35% Buffer B (0.1% formic acid in acetonitrile) was used to 
separate peptides at a flow rate of 300 nL/min. The full MS scan range was m/z 350–1600. 
The top 15 precursor ions were selected to perform MS/MS scans by high-energy collisional 
dissociation (HCD). Automated gain control (AGC) values were 1E6 and 1E5 for full MS and 
MS/MS scans, respectively. Normalized HCD energy was set to 22.0. Dynamic exclusion was 
enabled with the exclusion time of 30 sec. Lock mass calibration in full MS scan was 
implemented using polysiloxane ion, 371.10123. 
Data analysis: The acquired MS/MS spectra were searched through Mascot engine against the 
human Uniprot database consisting of forward and reversed protein sequences. The precursor 
ion tolerance was set to 10 ppm, and the fragment ion tolerance was set to 0.02 Da. 
Carbamidomethylation (57.0215) of cysteine was considered as a static modification, and 
biotinylation (226.0776) of lysine, oxidation (226.0776) of methionine and acetylation (42.0106) 
of protein N-terminus were considered as dynamic modifications. 1.0% False Discover Ratio 
(FDR) was used to filter the identified peptides. 
 
Morpholino sequences 
ccm1-MO: 5’- TGACCACCACTAACCTATTATGCCC-3’ 
klf2a-MO: 5’- AACAAGTGGCGTTTATTTACCTGTG-3’ 
klf2b-MO: 5’- TAAAATGCATTCTTACCGGTGTGAG-3’ 
adamts5-MO (X2a): 5’- CCCGCACAGATCCTGAATACACACA-3’ 




Primers used for qPCR analysis of cultured human endothelial gene expression 
MAP3K3 Forward: 5’-AGGCATTAGACTCGATCATGAAG-3’ 
MAP3K3 Reverse: 5’-CTCCCCATTGTGTTCAAACTTG-3’ 
KLF2 Forward: 5’-CTACACCAAGAGTTCGCATCTG-3’ 
KLF2 Reverse: 5’-CCGTGTGCTTTCGGTAGTG-3’ 
KLF4 Forward - 5’- AGAGTTCCCATCTCAAGGCA -3’ 
KLF4 Reverse - 5’- GTCAGTTCATCTGAGCGGG -3’ 
ADAMTS4 Forward - 5’- CTGACTTCCTGGACAATGGC -3’ 
ADAMTS4 Reverse - 5’- GCGGTCAGCATCATAGTCCT -3’ 
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